of the North Caucasus
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
русский
english
Site search
Correspondence address
310 Mira Street, Stavropol, Russia, 355017
Tel
+7 865 2352511, +7 865 2353229.
E-mail
medvestnik@stgmu.ru
The journal is included into The list of leading scientific periodicals.
The journal is included into VINITI database and is registered in Electronic scientific library.
The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.
Experience with high-throughput sequencing, bone marrow transplantation and targeted therapy for acute myeloid leukemia with a poor prognosis
[Notes from practice]
Alexander Vladimirovich Vinogradov; Daria Vyacheslavovna Litvinova; Tatyana Semyonovna Konstantinova; Julia Valentinovna Sveshnikova; Evgeny Shchetinin; Dmitry Bobryshev; Sergey Vladimirovich Sazonov;
The study presents a clinical case of treating acute myeloid leukemia with an unfavorable genetic prognosis due to genotyping by high-throughput sequencing. The patient underwent related allogeneic bone marrow transplantation with targeted chemotherapy. The disease manifested itself after a new coronavirus infection. Mutations R140Q in the IDH2 gene and P799S in the DNMT3A gene were detected by high throughput sequencing. Given the unfavorable genetic prognosis, bone marrow transplantation from an HLA compatible sibling was performed. On day 22, COVID-19 was detected, and ruxolitinib was added to the treatment. On the 25th day, hematopoiesis was restored with the preservation of clinical and hematological remission. Ten months after transplantation, a relapse was diagnosed, for which the patient started targeted therapy with 5-azacytidine with venetoclax in combination with transfusions of donor leukocytes. The second remission was achieved after the first course. The total duration of follow-up was 24 months.
References:
1. Ayyadurai V. A. S., Deonikar P., McLure K. G., Sakamoto K. M. Molecular systems architecture of interactome in the acute myeloid leukemia microenvironment. Cancers. 2022;14:756. https://doi.org/10.3390/cancers140307562
2. Vinogradov A. V., Rezaykin A. V., Sazonov S. V., Shchetinin E. V., Bobryshev D. V. Mutational status of acute myeloblastic leukemia with maturation (M2) in adult patients. Medical News of North Caucasus. 2021;16(1):18-21. https://doi.org/10.14300/mnnc.2021.16005
3. Kishtagari A., Levine R. L., Viny A. D. Driver mutations in acute myeloid leukemia. Curr. Opin. Hematol. 2020;27(2):49-57. https://doi.org/10.1097/MOH.0000000000000567
4. Strzelecka P. M., Damm F. Haematopoietic ageing through the lens of single-cell technologies. Dis. Model. Mech. 2021;14(1):dmm047340. https://doi.org/10.1242/dmm.047340
5. Venney D., Mohd-Sarip A., Mills K. I. The impact of epigenetic modifications in myeloid malignancies. Int. J. Mol. Sci. 2021;22(9):5013. https://doi.org/10.3390/ijms22095013
6. Wang F., Travins J., DeLaBarre B., Penard-Lacronique V., Schalm S. [et al.] Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622-626. https://doi.org/10.1126/science.1234769
Keywords: acute myeloid leukemia, COVID-19, bone marrow transplantation, DNMT3A gene, IDH2 gene, target therapy
Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy